Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770783 | 0.95 | GBA1 (0.47) | ALDH1A1GBA1SPHK2SPHK1HRH3 | |
| SCHEMBL27854377 | 0.81 | ALDH1A1 (0.47) | ALDH1A1GBA1KDM4ESPHK2SPHK1 | |
| SCHEMBL3810383 | 0.80 | ALDH1A1 (0.50) | ALDH1A1GBA1KDM4ESPHK2SPHK1 | |
| SCHEMBL10462905 | 0.79 | SPHK2 (0.50) | ALDH1A1GBA1KDM4ESPHK2SPHK1 | |
| SCHEMBL16226580 | 0.79 | L3MBTL1 (0.50) | ALDH1A1GBA1KDM4ESMN1; SMN2 | |
| SCHEMBL8327242 | 0.78 | SPHK2 (0.49) | ALDH1A1GBA1KDM4ESPHK2SPHK1 | |
| SCHEMBL27701484 | 0.78 | ALDH1A1 (0.44) | ALDH1A1GBA1KDM4ESPHK2SPHK1 | |
| SCHEMBL9274297 | 0.77 | CYP1A2 (0.47) | ALDH1A1GBA1SPHK2SPHK1ACHE | |
| SCHEMBL22341373 | 0.77 | CYP1A2 (0.47) | ALDH1A1GBA1SPHK2SPHK1ACHE | |
| SCHEMBL4770791 | 0.75 | ALDH1A1 (0.64) | ALDH1A1KDM4ESMN1; SMN2HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | ALDH1A1 708/4885GBA1 956/4885KDM4E 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.